#21046
Re: Novavax (NVAX): Un Nuevo Comienzo
Esa bajista #4 tiene muchas vidas ugh
Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 20 December 2021
This extraordinary meeting is organised to discuss the evaluation of the conditional marketing authorisation application for Nuvaxovid (also known as NVX-CoV2373), a COVID-19 vaccine developed by Novavax.
EMA will communicate on the outcome of the meeting.